Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034067 (
emphysema
)
11,506
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. Genetic variation at the glutathione S-transferase M1 locus (GSTM1) has been associated with a number of apparently unrelated cancers, including lung cancer.
Emphysema
is a common lung disease often found concomitant with lung cancer. Both
emphysema
and lung cancer may result from chemical and oxidative damage caused by reactive species present in cigarette smoke or released from neutrophils recruited following cigarette smoke induced injury. GSTM1 may protect against such damage through detoxification of cigarette smoke components. Polymorphism of this gene may thus influence susceptibility not just to lung cancer, but to other forms of lung disease. 2. Resection specimens from a group of 168 lung cancer patients were assessed for the presence of macroscopic centriacinar and panacinar
emphysema
. DNA was extracted from archival material and genotyped for the GSTM1 polymorphism using the polymerase chain reaction. A control group of 384
anonymous
blood donations was used to determine the frequency of the GSTM1 gene deletion in a random control population. Reverse transcription on lung tissue was performed to investigate mRNA expression of GSTM1 and GSTM4. 3. In 57 lung cancer cases with no
emphysema
there was no association with homozygous deletion of the GSTM1 gene (51% null in cancer and 53% null in control groups). However in 111 patients with
emphysema
and lung cancer there was an increase in the frequency of deletion (65%, P = 0.032) giving an odds ratio of 1.36(0.32-2.40). In 43 cases there was evidence of both centriacinar and panacinar
emphysema
. The frequency of GSTM1 deletion was 70% (Odds ratio 2.11, 0.97-3.25). Both GSTM1 and GSTM4 mRNAs were expressed in lung tissue. 4 These findings suggest that GSTM1 has a general but rather small protective effect against toxicological injury in the lung which is not specific to cancer. This is of relevance in considering the health effects of exposure to a wide range of reactive chemicals in the environment.
...
PMID:Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. 925 59
Aim-To investigate cytochrome P4501A1 (CYP1A1) polymorphism and susceptibility to
emphysema
and lung cancer.Methods-A novel polymerase chain reaction (PCR) for genotyping the CYP1A1 polymorphism, corresponding to putative low or high enzyme activity, was developed to genotype lung cancer resection samples which had been assessed macroscopically for the presence of centriacinar and panacinar
emphysema
. Samples were collected and genotyped from a group of patients with chronic obstructive airways disease. A control group of
anonymous
blood donations was genotyped to determine the basal levels of the polymorphism in the Scottish population.Results-The high activity allele of the CYP1A1 gene is associated with susceptibility to centriacinar
emphysema
and lung cancer but not panacinar
emphysema
. CYP1A1 polymorphism is not linked to lung cancer in the absence of
emphysema
, nor to chronic obstructive airways disease which is the clinical manifestation of
emphysema
, particularly of the panacinar type.Conclusions-Susceptibility to
emphysema
and lung cancer is associated with polymorphism of the P4501A1 gene. A trend towards damage of centriacinar pattern has been detected, which supports the theory that centriacinar
emphysema
results from local, direct damage to the respiratory bronchioles from exposure to cigarette smoke.
...
PMID:Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. 1669 9